Biofrontera (NASDAQ:BFRI – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Institutional & Insider Ownership
10.1% of Biofrontera shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Biofrontera and Unicycive Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Profitability
This table compares Biofrontera and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -13.78% | -145.81% | -31.30% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Earnings & Valuation
This table compares Biofrontera and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | 0.54 | -$10.54 million | ($0.45) | -3.36 |
| Unicycive Therapeutics | $680,000.00 | 217.07 | -$26.56 million | ($1.75) | -3.03 |
Biofrontera has higher revenue and earnings than Unicycive Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Summary
Unicycive Therapeutics beats Biofrontera on 9 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
